ES2656619T3 - Composición prebiótica de tilacoides - Google Patents
Composición prebiótica de tilacoides Download PDFInfo
- Publication number
- ES2656619T3 ES2656619T3 ES13763020.8T ES13763020T ES2656619T3 ES 2656619 T3 ES2656619 T3 ES 2656619T3 ES 13763020 T ES13763020 T ES 13763020T ES 2656619 T3 ES2656619 T3 ES 2656619T3
- Authority
- ES
- Spain
- Prior art keywords
- thylakoids
- composition
- use according
- bacteria
- lactobacillus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 210000002377 thylakoid Anatomy 0.000 title claims abstract description 93
- 239000000203 mixture Substances 0.000 title claims abstract description 52
- 235000013406 prebiotics Nutrition 0.000 title claims abstract description 23
- 241000894006 Bacteria Species 0.000 claims description 38
- 241000186660 Lactobacillus Species 0.000 claims description 32
- 210000003405 ileum Anatomy 0.000 claims description 24
- 241000186000 Bifidobacterium Species 0.000 claims description 19
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 18
- 239000006041 probiotic Substances 0.000 claims description 17
- 230000000529 probiotic effect Effects 0.000 claims description 17
- 235000018291 probiotics Nutrition 0.000 claims description 17
- 229940039696 lactobacillus Drugs 0.000 claims description 16
- 210000000936 intestine Anatomy 0.000 claims description 14
- 229930002875 chlorophyll Natural products 0.000 claims description 13
- 235000019804 chlorophyll Nutrition 0.000 claims description 13
- ATNHDLDRLWWWCB-AENOIHSZSA-M chlorophyll a Chemical compound C1([C@@H](C(=O)OC)C(=O)C2=C3C)=C2N2C3=CC(C(CC)=C3C)=[N+]4C3=CC3=C(C=C)C(C)=C5N3[Mg-2]42[N+]2=C1[C@@H](CCC(=O)OC\C=C(/C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)[C@H](C)C2=C5 ATNHDLDRLWWWCB-AENOIHSZSA-M 0.000 claims description 13
- 239000003795 chemical substances by application Substances 0.000 claims description 11
- 235000013305 food Nutrition 0.000 claims description 9
- 235000014655 lactic acid Nutrition 0.000 claims description 9
- 239000004310 lactic acid Substances 0.000 claims description 9
- 241000124008 Mammalia Species 0.000 claims description 7
- 241000186015 Bifidobacterium longum subsp. infantis Species 0.000 claims description 4
- 240000006024 Lactobacillus plantarum Species 0.000 claims description 4
- 235000013965 Lactobacillus plantarum Nutrition 0.000 claims description 4
- 235000009337 Spinacia oleracea Nutrition 0.000 claims description 4
- 229940004120 bifidobacterium infantis Drugs 0.000 claims description 4
- 229940072205 lactobacillus plantarum Drugs 0.000 claims description 4
- 241000195628 Chlorophyta Species 0.000 claims description 3
- 239000002417 nutraceutical Substances 0.000 claims description 3
- 235000021436 nutraceutical agent Nutrition 0.000 claims description 3
- 239000007764 o/w emulsion Substances 0.000 claims description 3
- 241000219315 Spinacia Species 0.000 claims 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 26
- 241000700159 Rattus Species 0.000 description 23
- 210000001072 colon Anatomy 0.000 description 21
- 238000004458 analytical method Methods 0.000 description 16
- 210000003608 fece Anatomy 0.000 description 16
- 230000001580 bacterial effect Effects 0.000 description 15
- 244000005709 gut microbiome Species 0.000 description 15
- 210000004877 mucosa Anatomy 0.000 description 14
- 102000004877 Insulin Human genes 0.000 description 13
- 108090001061 Insulin Proteins 0.000 description 13
- 241000736262 Microbiota Species 0.000 description 13
- 229940125396 insulin Drugs 0.000 description 13
- 238000003752 polymerase chain reaction Methods 0.000 description 13
- 235000005911 diet Nutrition 0.000 description 12
- 230000000694 effects Effects 0.000 description 12
- 239000000047 product Substances 0.000 description 12
- 241000192125 Firmicutes Species 0.000 description 11
- 108020004414 DNA Proteins 0.000 description 10
- 230000037213 diet Effects 0.000 description 10
- 230000000968 intestinal effect Effects 0.000 description 10
- 238000000513 principal component analysis Methods 0.000 description 10
- 206010012735 Diarrhoea Diseases 0.000 description 9
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 9
- 239000008103 glucose Substances 0.000 description 9
- 238000000034 method Methods 0.000 description 9
- 108020004465 16S ribosomal RNA Proteins 0.000 description 8
- 230000009286 beneficial effect Effects 0.000 description 8
- 230000037396 body weight Effects 0.000 description 8
- 230000008901 benefit Effects 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 6
- 208000008589 Obesity Diseases 0.000 description 6
- 230000003247 decreasing effect Effects 0.000 description 6
- 230000029087 digestion Effects 0.000 description 6
- 235000020824 obesity Nutrition 0.000 description 6
- 229920001817 Agar Polymers 0.000 description 5
- 206010022489 Insulin Resistance Diseases 0.000 description 5
- 241000186604 Lactobacillus reuteri Species 0.000 description 5
- 206010033307 Overweight Diseases 0.000 description 5
- 239000008272 agar Substances 0.000 description 5
- 206010012601 diabetes mellitus Diseases 0.000 description 5
- 229940001882 lactobacillus reuteri Drugs 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 238000012163 sequencing technique Methods 0.000 description 5
- 241000605059 Bacteroidetes Species 0.000 description 4
- 230000006583 body weight regulation Effects 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 210000004534 cecum Anatomy 0.000 description 4
- 230000002550 fecal effect Effects 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 238000003753 real-time PCR Methods 0.000 description 4
- 108091008146 restriction endonucleases Proteins 0.000 description 4
- 230000036186 satiety Effects 0.000 description 4
- 235000019627 satiety Nutrition 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 241000282412 Homo Species 0.000 description 3
- 235000019484 Rapeseed oil Nutrition 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 230000000112 colonic effect Effects 0.000 description 3
- 235000020940 control diet Nutrition 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 238000007446 glucose tolerance test Methods 0.000 description 3
- 230000036737 immune function Effects 0.000 description 3
- 210000005027 intestinal barrier Anatomy 0.000 description 3
- 230000007358 intestinal barrier function Effects 0.000 description 3
- 210000004347 intestinal mucosa Anatomy 0.000 description 3
- 208000002551 irritable bowel syndrome Diseases 0.000 description 3
- 244000005706 microflora Species 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 230000035699 permeability Effects 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 238000007894 restriction fragment length polymorphism technique Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 230000036642 wellbeing Effects 0.000 description 3
- 108091093088 Amplicon Proteins 0.000 description 2
- 241000193400 Bacillus simplex Species 0.000 description 2
- 241000606125 Bacteroides Species 0.000 description 2
- 102100025841 Cholecystokinin Human genes 0.000 description 2
- 101800001982 Cholecystokinin Proteins 0.000 description 2
- 241000588921 Enterobacteriaceae Species 0.000 description 2
- 241000579722 Kocuria Species 0.000 description 2
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 244000300264 Spinacia oleracea Species 0.000 description 2
- 241000191940 Staphylococcus Species 0.000 description 2
- 229960004308 acetylcysteine Drugs 0.000 description 2
- 239000011543 agarose gel Substances 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 229940107137 cholecystokinin Drugs 0.000 description 2
- 230000002354 daily effect Effects 0.000 description 2
- 230000000378 dietary effect Effects 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 239000003337 fertilizer Substances 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 230000004190 glucose uptake Effects 0.000 description 2
- 235000003642 hunger Nutrition 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 210000004379 membrane Anatomy 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- IOVGROKTTNBUGK-SJCJKPOMSA-N ritodrine Chemical compound N([C@@H](C)[C@H](O)C=1C=CC(O)=CC=1)CCC1=CC=C(O)C=C1 IOVGROKTTNBUGK-SJCJKPOMSA-N 0.000 description 2
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000012453 sprague-dawley rat model Methods 0.000 description 2
- 238000005728 strengthening Methods 0.000 description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 2
- 230000004580 weight loss Effects 0.000 description 2
- PHIQHXFUZVPYII-ZCFIWIBFSA-O (R)-carnitinium Chemical compound C[N+](C)(C)C[C@H](O)CC(O)=O PHIQHXFUZVPYII-ZCFIWIBFSA-O 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- RMTFNDVZYPHUEF-XZBKPIIZSA-N 3-O-methyl-D-glucose Chemical compound O=C[C@H](O)[C@@H](OC)[C@H](O)[C@H](O)CO RMTFNDVZYPHUEF-XZBKPIIZSA-N 0.000 description 1
- 208000032484 Accidental exposure to product Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 208000015943 Coeliac disease Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 238000007400 DNA extraction Methods 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 108010067770 Endopeptidase K Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 238000000729 Fisher's exact test Methods 0.000 description 1
- 102000012004 Ghrelin Human genes 0.000 description 1
- 101800001586 Ghrelin Proteins 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 241000186606 Lactobacillus gasseri Species 0.000 description 1
- 241001468157 Lactobacillus johnsonii Species 0.000 description 1
- 241000917009 Lactobacillus rhamnosus GG Species 0.000 description 1
- 102000016267 Leptin Human genes 0.000 description 1
- 108010092277 Leptin Proteins 0.000 description 1
- 102000004882 Lipase Human genes 0.000 description 1
- 108090001060 Lipase Proteins 0.000 description 1
- 239000004367 Lipase Substances 0.000 description 1
- 208000031964 Other metabolic disease Diseases 0.000 description 1
- 241000605861 Prevotella Species 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 238000010818 SYBR green PCR Master Mix Methods 0.000 description 1
- 108700043492 SprD Proteins 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 235000019486 Sunflower oil Nutrition 0.000 description 1
- 241000656145 Thyrsites atun Species 0.000 description 1
- 239000007984 Tris EDTA buffer Substances 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 231100000818 accidental exposure Toxicity 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 238000005251 capillar electrophoresis Methods 0.000 description 1
- 229960004203 carnitine Drugs 0.000 description 1
- 235000021466 carotenoid Nutrition 0.000 description 1
- 150000001747 carotenoids Chemical class 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 210000003763 chloroplast Anatomy 0.000 description 1
- 102000005311 colipase Human genes 0.000 description 1
- 108020002632 colipase Proteins 0.000 description 1
- 230000001332 colony forming effect Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000008094 contradictory effect Effects 0.000 description 1
- 238000013211 curve analysis Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000002074 deregulated effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 235000013367 dietary fats Nutrition 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 235000021050 feed intake Nutrition 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000012595 freezing medium Substances 0.000 description 1
- GNKDKYIHGQKHHM-RJKLHVOGSA-N ghrelin Chemical compound C([C@H](NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)CN)COC(=O)CCCCCCC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C1=CC=CC=C1 GNKDKYIHGQKHHM-RJKLHVOGSA-N 0.000 description 1
- 230000002641 glycemic effect Effects 0.000 description 1
- 230000007407 health benefit Effects 0.000 description 1
- 230000008821 health effect Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 238000010874 in vitro model Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 229940059406 lactobacillus rhamnosus gg Drugs 0.000 description 1
- 238000002350 laparotomy Methods 0.000 description 1
- 229940039781 leptin Drugs 0.000 description 1
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 description 1
- 235000019421 lipase Nutrition 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 235000020845 low-calorie diet Nutrition 0.000 description 1
- 230000001320 lysogenic effect Effects 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 238000000491 multivariate analysis Methods 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 239000011535 reaction buffer Substances 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- IKGXIBQEEMLURG-NVPNHPEKSA-N rutin Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-NVPNHPEKSA-N 0.000 description 1
- 239000006152 selective media Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000002600 sunflower oil Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 238000005382 thermal cycling Methods 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 239000001226 triphosphate Substances 0.000 description 1
- 235000011178 triphosphate Nutrition 0.000 description 1
- UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/21—Amaranthaceae (Amaranth family), e.g. pigweed, rockwort or globe amaranth
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/745—Bifidobacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/32—Foods, ingredients or supplements having a functional effect on health having an effect on the health of the digestive tract
- A23V2200/3202—Prebiotics, ingredients fermented in the gastrointestinal tract by beneficial microflora
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/32—Foods, ingredients or supplements having a functional effect on health having an effect on the health of the digestive tract
- A23V2200/3204—Probiotics, living bacteria to be ingested for action in the digestive tract
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/20—Natural extracts
- A23V2250/206—Bacterial extracts
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/20—Natural extracts
- A23V2250/21—Plant extracts
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Mycology (AREA)
- Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Botany (AREA)
- Polymers & Plastics (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- General Preparation And Processing Of Foods (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE1251019 | 2012-09-11 | ||
| SE1251019 | 2012-09-11 | ||
| PCT/EP2013/068656 WO2014040962A1 (en) | 2012-09-11 | 2013-09-10 | Prebiotic thylakoid composition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2656619T3 true ES2656619T3 (es) | 2018-02-27 |
Family
ID=49209335
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES13763020.8T Active ES2656619T3 (es) | 2012-09-11 | 2013-09-10 | Composición prebiótica de tilacoides |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20150209396A1 (enExample) |
| EP (1) | EP2895012B1 (enExample) |
| JP (1) | JP6475162B2 (enExample) |
| KR (1) | KR20150053769A (enExample) |
| CN (1) | CN104780783A (enExample) |
| AU (1) | AU2013314410B2 (enExample) |
| BR (1) | BR112015005355A2 (enExample) |
| CA (1) | CA2884281C (enExample) |
| DK (1) | DK2895012T3 (enExample) |
| ES (1) | ES2656619T3 (enExample) |
| NO (1) | NO2895012T3 (enExample) |
| WO (1) | WO2014040962A1 (enExample) |
| ZA (1) | ZA201502431B (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3082466T3 (da) * | 2013-12-18 | 2019-10-07 | Thylabisco Ab | Anvendelse af thylakoider til formindskelse af trangen til velsmagende næringsmidler |
| KR20200091499A (ko) | 2015-05-06 | 2020-07-30 | 스니프르 테크놀로지스 리미티드 | 미생물 개체군 변경 및 미생물군 변형 |
| JP6551934B2 (ja) * | 2015-12-18 | 2019-07-31 | 森永乳業株式会社 | ビフィドバクテリウム属細菌および／または乳酸菌の増殖促進および／または減少抑制剤 |
| JP7244977B2 (ja) * | 2016-03-11 | 2023-03-23 | シオノギヘルスケア株式会社 | 腸内細菌叢調整用組成物 |
| GB202209518D0 (en) | 2022-06-29 | 2022-08-10 | Snipr Biome Aps | Treating & preventing E coli infections |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69908306T2 (de) | 1998-02-24 | 2003-11-27 | Arla Foods Amba, Viby J | Verwendung von t-tagatose als praebiotischen nahrungsmittelzusatz |
| US20030165557A1 (en) * | 2000-09-19 | 2003-09-04 | Sunstar, Inc. | Food, medicine and method relating to Bifidobacterium proliferation promoting action, allergy preventive action and human cholesterol lowering action |
| JP2006025669A (ja) * | 2004-07-14 | 2006-02-02 | Kumamotoken Kajitsu Nogyo Kyodo Kumiai Rengokai | 飲料の製造法 |
| PL1833291T3 (pl) * | 2004-12-30 | 2017-05-31 | Commonwealth Scientific And Industrial Research Organisation | Metoda i środki poprawy stanu zdrowia jelit |
| HUE040501T2 (hu) | 2005-06-10 | 2019-03-28 | Thylabisco Ab | Növényi sejtmembrán alkalmazása elhízás kezelésére |
| JP4819767B2 (ja) * | 2006-12-12 | 2011-11-24 | 株式会社エス・エフ・シー | イグサ青汁 |
| US20080175899A1 (en) * | 2007-01-19 | 2008-07-24 | Ross Mairi R | Formulation for promoting sinus health in nasal cavities |
| CN101278752A (zh) * | 2008-01-29 | 2008-10-08 | 梁季鸿 | 即食卡尼汀天然果蔬饮料干粉系列配方及生产工艺 |
| KR20110043657A (ko) | 2008-07-14 | 2011-04-27 | 틸라비스코 아베 | 틸라코이드를 제조하기 위한 대규모 방법 |
| ES2763137T3 (es) * | 2009-06-19 | 2020-05-27 | Dupont Nutrition Biosci Aps | Bifidobacterias para el tratamiento de diabetes y afecciones relacionadas |
| US20140037774A1 (en) * | 2011-02-25 | 2014-02-06 | Thylabisco Ab | Composition comprising thylakoids for delaying the uptake of molecules |
-
2013
- 2013-09-10 DK DK13763020.8T patent/DK2895012T3/en active
- 2013-09-10 ES ES13763020.8T patent/ES2656619T3/es active Active
- 2013-09-10 CA CA2884281A patent/CA2884281C/en active Active
- 2013-09-10 BR BR112015005355A patent/BR112015005355A2/pt not_active Application Discontinuation
- 2013-09-10 NO NO13763020A patent/NO2895012T3/no unknown
- 2013-09-10 WO PCT/EP2013/068656 patent/WO2014040962A1/en not_active Ceased
- 2013-09-10 US US14/426,541 patent/US20150209396A1/en not_active Abandoned
- 2013-09-10 CN CN201380052341.7A patent/CN104780783A/zh active Pending
- 2013-09-10 KR KR1020157008166A patent/KR20150053769A/ko not_active Withdrawn
- 2013-09-10 EP EP13763020.8A patent/EP2895012B1/en active Active
- 2013-09-10 AU AU2013314410A patent/AU2013314410B2/en active Active
- 2013-09-10 JP JP2015530443A patent/JP6475162B2/ja active Active
-
2015
- 2015-04-10 ZA ZA2015/02431A patent/ZA201502431B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20150209396A1 (en) | 2015-07-30 |
| NO2895012T3 (enExample) | 2018-03-17 |
| JP2015533484A (ja) | 2015-11-26 |
| EP2895012B1 (en) | 2017-10-18 |
| CA2884281C (en) | 2021-01-05 |
| KR20150053769A (ko) | 2015-05-18 |
| CA2884281A1 (en) | 2014-03-20 |
| EP2895012A1 (en) | 2015-07-22 |
| DK2895012T3 (en) | 2018-01-22 |
| AU2013314410B2 (en) | 2017-02-23 |
| AU2013314410A1 (en) | 2015-04-16 |
| CN104780783A (zh) | 2015-07-15 |
| ZA201502431B (en) | 2017-11-29 |
| WO2014040962A1 (en) | 2014-03-20 |
| BR112015005355A2 (pt) | 2017-08-08 |
| JP6475162B2 (ja) | 2019-02-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Lim et al. | Lactobacillus sakei OK67 ameliorates high-fat diet–induced blood glucose intolerance and obesity in mice by inhibiting gut microbiota lipopolysaccharide production and inducing colon tight junction protein expression | |
| ES2960781T3 (es) | Uso de comunidades microbianas para la salud humana y animal | |
| Wasilewski et al. | Beneficial effects of probiotics, prebiotics, synbiotics, and psychobiotics in inflammatory bowel disease | |
| ES2886951T3 (es) | Composición para su uso en la modulación de la microbiota | |
| ES2884049T3 (es) | Bacterias de la familia christensenellaceae para su uso como un medicamento, en particular para tratar el sobrepeso, la obesidad, las enfermedades cardiometabólicas y las enfermedades inflamatorias del intestino | |
| ES2610829T3 (es) | Cepa de Bifidobacterium | |
| Su et al. | Lotus seed oligosaccharides at various dosages with prebiotic activity regulate gut microbiota and relieve constipation in mice | |
| ES2611277T3 (es) | Péptidos contra una infección por rotavirus | |
| CN110201003A (zh) | 微生物区系的组合物及与其相关的方法 | |
| TW200902040A (en) | Probiotics in a pre-and/or post-surgical environment | |
| JP6475162B2 (ja) | プレバイオティックチラコイド組成物 | |
| Loo et al. | A current overview of next-generation probiotics and their prospects in health and disease management | |
| Ho et al. | Effects of supplementation of citrulline and Lactobacillus helveticus ASCC 511 on intestinal epithelial cell integrity | |
| Golchin et al. | The role of probiotics in tissue engineering and regenerative medicine | |
| BRPI0407176B1 (pt) | composições compreendendo uma ou mais cepas de bifidobacterium e seus usos | |
| Xu et al. | In vitro screening of Lactiplantibacillus plantarum with probiotic properties and anti-colon cancer potential | |
| Ghosh | Role of probiotics in modulation of stem cell progeny in human gastrointestinal disorders | |
| Jangra et al. | Living medicines for health and disease management | |
| Naghmouchi | RELEVANCE OF GUT MICROBIOTA IN HEALTH, DISEASE AND PRODUCTION OF ANTIMICROBIAL SUBSTANCES | |
| Code | Proprietary human strain probiotic for extra daily support | |
| Nongrum | Effects of Gut Microbiota on Cardiovascular Diseases | |
| Tan et al. | Beta-1 blocker reduces inflammation and preserves intestinal barrier function after open abdominal surgery | |
| Loh et al. | Roles of Probiotics on Lifelong Diversifications of Gut Microbiota | |
| Choi et al. | Development of livestock feed additives using porcine blood cells | |
| IL321563A (en) | Drinking cure beverage comprising three components for building up, promoting and maintaining intestinal health |